Phaseline

Targets › IL7

IL7 (Interleukin-7): drug programs, companies and trials

6 programs from 4 companies in 7 trials: 5 Phase 1, 2 Phase 2; Oncology, Infectious disease; next expected readout Nov 2026.

Hematopoietic cytokine that plays an essential role in the development, expansion, and survival of naive and memory T-cells and B-cells thereby regulating the number of mature lymphocytes and maintaining lymphoid homeostasis. Mechanistically, exerts its biological effects through a receptor composed of IL7RA subunit and the cytokine receptor common subunit gamma/CSF2RG. Binding to the receptor leads to activation of…. (UniProt, P13232)

Open in Phaseline: the race on IL7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mayo ClinicEfineptakin alfa
IL-7 hybrid Fc fusion protein; enhances T cell proliferation and survival
IL7Phase 2High Grade Astrocytic TumorSep 2031
National Cancer Institute (NCI)CYT107
Recombinant glycosylated human interleukin-7
IL7Phase 2Kaposi SarcomaJan 2036
National Institute of Allergy and Infectious Diseases (NIAID)Recombinant human interleukin (IL) 7-hyFc (NT-I7, Efineptakin Alfa)
Recombinant human IL-7 fusion protein (IL-7-hyFc)
IL7Phase 1Idiopathic CD4 LymphopeniaNov 2026
Washington University School of MedicineRecombinant human interleukin-7 (CYT107)
Interleukin-7 receptor agonist; promotes T cell reconstitution
IL7Phase 1Multiple MyelomaAug 2027
Washington University School of MedicineNT-I7
Recombinant human IL-7 (interleukin-7); promotes CAR-T cell expansion and efficacy
IL7Phase 1Large B-cell Lymphoma; Multiple MyelomaNov 2027
Washington University School of MedicinerhIL-7-hyFc
Recombinant human IL-7 with hyper-stable Fc domain
IL7Phase 1GliomaApr 2028

Conditions

Multiple Myeloma (2) Large B-cell Lymphoma (1) High Grade Astrocytic Tumor (1) Kaposi Sarcoma (1) Idiopathic CD4 Lymphopenia (1) Glioma (1)

Modalities

protein or peptide (2), mixed (2), small molecule (2)

Companies

Washington University School of Medicine (3) Mayo Clinic (1) National Cancer Institute (NCI) (1) National Institute of Allergy and Infectious Diseases (NIAID) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.